Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Azurrx Biopharma Inc (AZRX)

0.8012   0.011 (1.39%) 10-24 13:45
Open: 0.804 Pre. Close: 0.7902
High: 0.804 Low: 0.7801
Volume: 25,018 Market Cap: 23M
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.801 - 0.804 0.804 - 0.807
Low: 0.771 - 0.775 0.775 - 0.779
Close: 0.793 - 0.8 0.8 - 0.805

Technical analysis

as of: 2020-10-23 4:40:58 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 0.98     One year: 1.15
Support: Support1: 0.72    Support2: 0.65
Resistance: Resistance1: 0.84    Resistance2: 0.98
Pivot: 0.78
Moving Average: MA(5): 0.80     MA(20): 0.76
MA(100): 0.87     MA(250): 0.84
MACD: MACD(12,26):     Signal(9):
Stochastic oscillator: %K(14,3): 73.64     %D(3): 78.32
RSI: RSI(14): 54.29
52-week: High: 1.94  Low: 0.37  Change(%): 17.8
Average Vol(K): 3-Month: 36246  10-Days: 13652

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
AZRX has closed below upper band by 23.9%. Bollinger Bands are 58% narrower than normal. The narrow width of the bands suggests low volatility as compared to AZRX's normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Wed, 14 Oct 2020
AzurRx BioPharma (AZRX) Reports Additional Clinical Trial Sites in Turkey for Phase 2 Combination Therapy Trial of MS1819 in CF - StreetInsider.com

Wed, 14 Oct 2020
AzurRx BioPharma Activates Additional Clinical Trial Sites in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis - GlobeNewswire

Wed, 07 Oct 2020
AzurRx BioPharma CEO Issues Letter to Shareholders - GlobeNewswire

Tue, 15 Sep 2020
AzurRx BioPharma Announces Two Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference - GlobeNewswire

Mon, 31 Aug 2020
AzurRx BioPharma to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference (September 14) and the LD 500 Virtual Conference (September 4) - GlobeNewswire

Mon, 17 Aug 2020
AzurRx BioPharma Initiates European Arm of Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis - GlobeNewswire

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Underperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Outperform Debt to Equity: Underperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 29
Shares Float (M) 24
% Held by Insiders 17.79
% Held by Institutions 5.11
Shares Short (K) 178
Shares Short P. Month (K) 102

Stock Financials

EPS -0.580
EPS Est This Year -0.850
EPS Est Next Year -0.670
Book Value (p.s.) -0.030
Profit Margin
Operating Margin
Return on Assets (ttm) -79.9
Return on Equity (ttm) -1435.0
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -0.349
Qtrly Earnings Growth
Operating Cash Flow (M) -10
Levered Free Cash Flow (M) -4

Stock Valuations

PE Ratio -1.38
PEG Ratio
Price to Book value -26.71
Price to Sales
Price to Cash Flow -2.28

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.